Chalcomoracin
Chalcomoracin is an orally active anticancer agent. Chalcomoracin exhibits anticancer, antibacterial, and α-glucosidase inhibitory activities, with an IC50 of 14.23 µM against yeast α-glucosidase and an IC50 of 5.5 μM against FabI of Staphylococcus aureus. Chalcomoracin reduces the phosphorylation levels of ERK, JNK, and P38; enhances the phosphorylation level of ERK1/2; regulates the MAPK, mTOR, AKT, and p53 signaling pathways; upregulates the expression of Chop, Bip, PINK1, GRP78, and GADD153; and downregulates the expression of Alix. Chalcomoracin induces apoptosis (apoptosis), endoplasmic reticulum stress (endoplasmic reticulum stress), paraptosis (paraptosis), ROS production, mitophagy (mitophagy), and autophagy (autophagy); it inhibits cancer cell viability, colony-forming ability, migration, invasion, proliferation, tumorigenesis, fatty acid synthesis, S. aureus growth, vitreous-stimulated retinal cell activity, and cell cycle progression at the G0/G1 phase. Chalcomoracin can be used in research related to hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, prostate cancer, proliferative vitreoretinopathy, pancreatic cancer, diabetes, and bacterial infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 76472-89-4
- Formel: C39H36O9
- Molecular Weight:648.70
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
|
α-Glucosidase 14.23 μM (IC50) |
ERK |
JNK |
p38 |
ERK1 |
ERK2 |
MAPK |
mTOR |
Akt |
p53 |
Chop |
Bip |
PINK1 |
GRP78 |
GADD153 |
Alix |
α-glucosidase |
In Vitro
Chalcomoracin (1.5-6 µM; 24-72 h) significantly reduces the viability of human Hep3B and SNU-387 HCC cells in a time- and concentration-dependent manner, with the most potent effect at 6 µM over 72 h[1].
Chalcomoracin (1.5-6 µM; 24 h) inhibits clonogenic proliferation of human Hep3B and SNU-387 HCC cells in a concentration-dependent manner, with the strongest effect at 6 µM[1].
Chalcomoracin (1.5-6 µM; 48 h) suppresses activation of the MAPK pathway in human Hep3B and SNU-387 HCC cells by reducing p-ERK, p-P38, and p-JNK protein levels after 48 h of treatment[1].
Chalcomoracin (2-32 μM; 24-72 h) dose-dependently inhibits the viability of human non-small cell lung cancer H460, A549, and PC-9 cells, with IC50 values ranging from 4.8 μM to 12.3 μM across 24, 48, and 72 h incubations[2].
Chalcomoracin (2-6 μM; 48 h) induces dose-dependent cytoplasmic vacuolation in human non-small cell lung cancer H460, A549, and PC-9 cells, with 6 μM CMR causing 24.5% to 36.6% vacuolated cells after 48 h incubation[2].
Chalcomoracin (2-6 μM; 2 h) pretreatment enhances the radiosensitivity of human non-small cell lung cancer H460 and A549 cells, with a maximum sensitizer enhancement ratio of 1.35 (H460) and 1.28 (A549) at 6 μM CMR[2].
Combination treatment with chalcomoracin and ionizing radiation exerts a synergistic cytotoxic effect on human non-small cell lung cancer H460 and A549 cells[2].
Chalcomoracin (2.5-10 μM; 24-72 h) potently inhibits viability and induces death in MDA-MB-231, PC-3, and LNCaP cancer cells with IC50 values of 6 μM (MDA-MB-231, PC-3) and 8 μM (LNCaP) at 48 h, while showing much lower cytotoxicity toward normal mammary epithelial MCF-10A and normal prostate RWPE-2 cells[3].
Chalcomoracin (6 μM; 24-48 h) induces paraptotic, non-apoptotic cell death characterized by ER-derived cytoplasmic vacuolation in MDA-MB-231 and PC-3 cells, but not in LNCaP cells[3].
Chalcomoracin (2.5-40 μM; 24-72 h) exhibits dose- and time-dependent cytotoxicity to ARPE-19 retinal pigment epithelial cells, with an IC50 of 35.5 μM at 72 hours, and 5 μM Chalcomoracin is non-toxic to these cells[4].
Chalcomoracin (5 μM; 8 h) prevents vitreous-induced activation of AKT and reduction of p53 expression in ARPE-19 retinal pigment epithelial cells[4].
Chalcomoracin (5 μM; 48 h) completely blocks vitreous-induced proliferation of ARPE-19 retinal pigment epithelial cells[4].
Chalcomoracin (2.5-10 μM; 24 h) dose-dependently blocks vitreous-induced migration of ARPE-19 retinal pigment epithelial cells[4].
Chalcomoracin (5 μM; 48 h) completely blocks vitreous-induced collagen gel contraction by ARPE-19 retinal pigment epithelial cells[4].
Chalcomoracin (2.5-10 μM; 24-72 h) inhibits PANC-1 cells viability in a concentration- and time-dependent manner[5].
Chalcomoracin (6-8 μM; 48 h) persistently suppresses clonogenic capacity and long-term proliferation of pancreatic cancer cells[5].
Chalcomoracin (1.5-6 µM; 24 h) promotes apoptosis of human Hep3B and SNU-387 HCC cells in a concentration-dependent manner, with significant effects starting at 3 µM and the strongest effect at 6 µM after 24 h[1].
Chalcomoracin (1.5-6 µM; 24 h) modulates apoptosis-related protein expression in human Hep3B and SNU-387 HCC cells, reducing Bcl2 levels and increasing Bax, cleaved caspase-3, and cleaved PARP levels in a concentration-dependent manner[1].
Chalcomoracin (1.5-6 µM; 24 h) induces endoplasmic reticulum stress in human Hep3B and SNU-387 HCC cells, increasing ATF4, GRP78, and CHOP protein levels in a concentration-dependent manner[1].
Chalcomoracin (1.5-6 µM; 24 h) reduces MMP2 and MMP9 protein levels in human Hep3B and SNU-387 HCC cells in a concentration-dependent manner, supporting its anti-invasive activity[1].
Chalcomoracin (1.5-6 µM; 24 h pretreatment) suppresses migration and invasion of human Hep3B and SNU-387 HCC cells in a concentration-dependent manner, with the strongest effect at 6 µM after 24 h of pretreatment[1].
Chalcomoracin (2-6 μM; 48 h) induces endoplasmic reticulum dilation-derived cytoplasmic vacuolation in a dose-dependent manner in human non-small cell lung cancer H460 and A549 cells after 48 h incubation[2].
Chalcomoracin (6 μM; 48 h) induces endoplasmic reticulum swelling and cytoplasmic vacuolation without apoptotic nuclear changes in human non-small cell lung cancer H460 and A549 cells[2].
Chalcomoracin (6 μM; 2 h preincubation, 48 h post-treatment) enhances radiosensitivity in human non-small cell lung cancer H460 and A549 cells by increasing radiation-induced cytoplasmic vacuolation[2].
Chalcomoracin (6 μM; 2 h preincubation, 48 h post-radiation) increases endoplasmic reticulum stress marker expression in combination with ionizing radiation in human non-small cell lung cancer H460 and A549 cells, with H460 cells showing increased IRE1, ATF6, and p-PERK levels and A549 cells showing only increased IRE1 levels[2].
Chalcomoracin (2-8 μM; 48 h) does not induce significant apoptosis in human non-small cell lung cancer H460 and A549 cells at doses up to 6 μM after 48 h incubation, with only minimal apoptosis observed at 8 μM[2].
Chalcomoracin (6 μM; 2 h preincubation, 48 h post-treatment) does not enhance ionizing radiation-induced apoptosis in human non-small cell lung cancer H460 and A549 cells after 48 h post-treatment[2].
Chalcomoracin (2-6 μM; 48 h) dose-dependently upregulates endoplasmic reticulum stress markers Bip and Chop in human non-small cell lung cancer H460 and A549 cells after 48 h incubation, with H460 cells showing increased IRE1, p-PERK, and ATF6 expression and A549 cells showing only increased IRE1 expression, without activating apoptosis-related caspase-3 or PARP[2].
Chalcomoracin-mediated paraptosis is dependent on endoplasmic reticulum stress, as Bip knockdown reduces both chalcomoracin-induced cell death and cytoplasmic vacuolation in human non-small cell lung cancer H460 cells[2].
Chalcomoracin (6-8 μM; 48 h) dose-dependently activates ER stress and mitophagy, and downregulates the paraptosis inhibitor Alix, in MDA-MB-231 and PC-3 cells, while having no effect on these pathways in LNCaP cells[3].
Chalcomoracin (1.875-15 μM; 48 h) requires active protein synthesis for its induced paraptosis, mitophagy activation, and cell death in MDA-MB-231 and PC-3 cells, as pre-treatment with 5 μg/mL CHX for 1 h inhibits these effects[3].
Chalcomoracin (1-6 μM; 24-48 h)-induced paraptosis in MDA-MB-231 and PC-3 cells requires calpain activity and MAPK (ERK1/2) signaling, as pre-treatment with 10 μM E-64d or 10 μM U0126 inhibits cytoplasmic vacuolation and related protein changes[3].
Chalcomoracin (6 μM; 48 h) regulates paraptosis and mitophagy-related gene expression in MDA-MB-231 and PC-3 cells, increasing PINK1, GADD153, and GRP78 mRNA and decreasing Alix mRNA, while having no effect on these genes in LNCaP cells[3].
Chalcomoracin (6 μM; 48 h)-induced paraptosis in cancer cells requires PINK1, as ectopic PINK1 expression sensitizes LNCaP cells to CMR-induced paraptosis, and PINK1 knockdown protects MDA-MB-231 cells from these effects[3].
Chalcomoracin (6-10 μM; 48 h) induces complete autophagic flux, elevates autophagy turnover and promotes the formation of autophagic vacuoles in PANC-1 pancreatic cancer cells[5].
Chalcomoracin (2-6 μM; 6-48 h)-induced paraptosis in MDA-MB-231 and PC-3 cells is mediated by ROS production, loss of mitochondrial membrane potential, and dysregulated calcium homeostasis, as pre-treatment with NAC, BAPTA, or BAPTA-AM inhibits these effects[3].
Chalcomoracin (6-8 μM; 48 h) blocks pancreatic cancer proliferation by triggering G0/G1 cell cycle arrest[5].
Chalcomoracin (6-8 μM; 48 h) enhances lysosomal acidification to facilitate autophagic substrate degradation in PANC-1 cells[5].
Chalcomoracin (6-10 μM; 48 h) activates autophagy via inhibitory regulation of mTOR signaling cascade[5].
Chalcomoracin (6-10 μM; 48 h) induces massive intracellular ROS production in PANC-1 cells; ROS acts as upstream initiating signal of downstream events[5].
Chalcomoracin (6-10 μM; 48 h) has its induced apoptosis and growth inhibition in human pancreatic cancer PANC-1 cells alleviated by inhibition of autophagy via Atg5/Atg7 knockdown or Wortmannin (HY-10197) pretreatment[5].
Chalcomoracin (1.5625-200 μM; 10 min pre-incubation with α-glucosidase, 30 min incubation with PNPG) potently inhibits yeast α-glucosidase with an IC50 of 14.23 μM[6].
Chalcomoracin (20-50 μM) inhibits yeast α-glucosidase via a mixed competitive and non-competitive mode, as indicated by increasing Km and decreasing Vmax with rising Chalcomoracin concentrations[6].
Chalcomoracin (200 μM; 300 s intervals between 30 total 5-μL injections at 37 °C) binds to yeast α-glucosidase in an entropy-driven spontaneous reaction, with hydrophobic interactions playing a leading role in the binding process[6].
Chalcomoracin binds firmly to yeast α-glucosidase via a combination of hydrophobic interactions, hydrogen bonds, and cation-π interactions within the enzyme's hydrophobic pocket[6].
Chalcomoracin inhibits purified Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI) with an IC50 of 5.5 μM[7].
Chalcomoracin inhibits the growth of Staphylococcus aureus with a minimum inhibitory concentration (MIC) of 4 µg/mL[7].
Chalcomoracin inhibits fatty acid synthesis in Staphylococcus aureus, without affecting the organism's protein synthesis[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Significantly reduced cell viability in both Hep3B and SNU-387 cells in a time- and concentration-dependent manner.
Showed the strongest reduction at 6 µM after 72 h of incubation.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h
-
Result:Decreased colony formation capacity in both cell lines in a concentration-dependent manner.
Caused a significant reduction at 1.5 µM, while 3 µM and 6 µM caused stronger, dose-dependent reductions.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h
-
Result:Promoted apoptosis in both cell lines in a concentration-dependent manner.
Showed no significant effect at 1.5 µM, while 3 µM caused a significant increase in apoptosis rate, and 6 µM caused a robust, highly significant increase.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h
-
Result:Reduced relative expression of anti-apoptotic Bcl2 and increased relative expression of pro-apoptotic Bax, cleaved caspase-3, and cleaved PARP in both cell lines in a concentration-dependent manner.
Showed significant changes at 1.5 µM and stronger, highly significant changes at 3 µM and 6 µM.\n
Increased relative expression of ER stress-related proteins ATF4, GRP78, and CHOP in both cell lines in a concentration-dependent manner.
Showed significant changes at 1.5 µM and stronger, highly significant changes at 3 µM and 6 µM.\n
Reduced relative expression of invasion-related proteins MMP2 and MMP9 in both cell lines in a concentration-dependent manner.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h
-
Result:Inhibited cell migration.
-
Cell Line:Human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5 µM, 3 µM, 6 µM
-
Incubation Time:24 h
-
Result:Inhibited cell invasion.
-
Cell Line:human hepatocellular carcinoma (HCC) Hep3B, SNU-387
-
Concentration:1.5-6 µM
-
Incubation Time:48 h
-
Result:Showed significant reductions at 1.5 µM and stronger, highly significant reductions at 3 µM and 6 µM.
Reduced relative expression of phosphorylated ERK (p-ERK), phosphorylated P38 (p-P38), and phosphorylated JNK (p-JNK) in both cell lines compared to control, with no clear concentration dependence observed.
Showed significant reductions at all tested concentrations.
-
Cell Line:Human non-small cell lung cancer H460, A549, and PC-9 cells
-
Concentration:2 μM, 4 μM, 8 μM, 16 μM, 32 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Dose-dependently decreased the viability of H460, A549, and PC-9 cells.
Reduced cell viability with IC50 values of 10.8 μM (H460), 10.1 μM (A549), and 12.3 μM (PC-9) at 24 h.
Reduced cell viability with IC50 values of 6.1 μM (H460), 6.3 μM (A549), and 8.9 μM (PC-9) at 48 h.
Reduced cell viability with IC50 values of 4.8 μM (H460), 5.7 μM (A549), and 7.9 μM (PC-9) at 72 h.
-
Cell Line:Human non-small cell lung cancer H460 and A549 cells
-
Concentration:2 μM, 4 μM, 6 μM
-
Incubation Time:48 h
-
Result:Showed that the edges of all cytoplasmic vacuoles in CMR-treated cells were stained with calreticulin, confirming vacuoles originated from ER dilation.
Increased the percentage of vacuolated cells in a dose-dependent manner in both cell lines, with significant increases observed at 6 μM CMR compared to controls.
-
Cell Line:Human non-small cell lung cancer H460 and A549 cells
-
Concentration:2 μM, 4 μM, 6 μM, 8 μM
-
Incubation Time:48 h
-
Result:Did not induce significant apoptosis in H460 and A549 cells at doses up to 6 μM.
Caused only slight increases in apoptotic cell death detected at the highest tested dose (8 μM) in both cell lines.
-
Cell Line:Human non-small cell lung cancer H460 and A549 cells
-
Concentration:2 μM, 4 μM, 6 μM
-
Incubation Time:48 h
-
Result:Dose-dependently increased the expression of ER stress markers Bip and Chop in both cell lines.
Increased expression of IRE1, p-PERK, and ATF6 at 6 μM CMR in H460 cells.
Increased only IRE1 expression at 6 μM CMR in A549 cells.
Detected no obvious changes in Alix, LC3B, caspase-3 (full-length or cleaved), or PARP (full-length or cleaved) protein levels in either cell line.
-
Cell Line:human non-small cell lung cancer H460 and A549 cells
-
Concentration:6 μM
-
Incubation Time:2 h (preincubated prior to IR treatment); 48 h (post-treatment analysis)
-
Result:Had no effect on IR-induced apoptosis in either cell line.
-
Cell Line:Human non-small cell lung cancer H460 and A549 cells
-
Concentration:6 μM
-
Incubation Time:2 h (preincubated prior to IR treatment); 48 h (post-treatment analysis)
-
Result:Dramatically increased the percentage of vacuolated cells: in H460 cells, vacuolation increased from 23.5% to 42.2%; in A549 cells, vacuolation increased from 18.1% to 33.8% after IR exposure.
Showed no such increase in irradiated control cells without CMR pretreatment.
-
Cell Line:Human non-small cell lung cancer H460 and A549 cells
-
Concentration:6 μM
-
Incubation Time:2 h (preincubated prior to IR treatment); 48 h (post-radiation analysis)
-
Result:Increased Bip and Chop protein expression only in cells treated with the combination of CMR and IR.
Increased IRE1, ATF6, and p-PERK levels in response to IR in H460 cells pretreated with 6 μM CMR.
Increased only IRE1 protein levels in response to combined treatment in A549 cells.
-
Cell Line:Human triple-negative breast cancer MDA-MB-231 cells, human prostate cancer PC-3 cells, human prostate cancer LNCaP cells, human normal mammary epithelial MCF-10A cells, human normal prostate RWPE-2 cells
-
Concentration:2.5 μM, 5 μM, 7.5 μM, 10 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Inhibited cell viability in a dose- and time-dependent manner in all three cancer cell lines, with IC50 values of 6 μM for MDA-MB-231 and PC-3 cells, and 8 μM for LNCaP cells after 48 h exposure.
Induced dose-dependent cell death (measured by PI uptake) in MDA-MB-231, PC-3, and LNCaP cells after 48 h treatment.
Showed significantly lower cytotoxicity in normal MCF-10A and RWPE-2 cells at equivalent concentrations.
-
Cell Line:Human triple-negative breast cancer MDA-MB-231 cells, human prostate cancer PC-3 cells, human prostate cancer LNCaP cells, human normal mammary epithelial MCF-10A cells
-
Concentration:6 μM, 7 μM, 8 μM
-
Incubation Time:48 h
-
Result:Dose-dependently increased expression of ER stress markers GRP78 and GADD153, accumulated ubiquitinated proteins, increased LC3-II levels (a marker of autophagosome formation), upregulated mitophagy regulator PINK1, and downregulated paraptosis inhibitor Alix in MDA-MB-231 and PC-3 cells.
Did not induce these changes in LNCaP cells.
Only weakly induced these changes in MCF-10A cells.
Confirmed co-localization of GFP-LC3 puncta with mitochondria (indicative of mitophagy) in CMR-treated MDA-MB-231 and PC-3 cells via confocal microscopy.
-
Cell Line:Human triple-negative breast cancer MDA-MB-231 cells, human prostate cancer PC-3 cells, human prostate cancer LNCaP cells
-
Concentration:6 μM
-
Incubation Time:48 h
-
Result:Increased mRNA expression of PINK1, GADD153, and GRP78, and decreased mRNA expression of Alix in MDA-MB-231 and PC-3 cells.
Left caspase-3 and PARP gene expression unchanged in MDA-MB-231 and PC-3 cells.
Caused no significant changes in these gene expressions in LNCaP cells.
-
Cell Line:ARPE-19 retinal pigment epithelial cells
-
Concentration:2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Showed dose- and time-dependent cytotoxicity to ARPE-19 cells.
Reached an IC50 of 35.5 μmol/L at 72 hours.
Did not cause obvious toxicity to ARPE-19 cells at 5 μmol/L.
-
Cell Line:Serum-starved ARPE-19 retinal pigment epithelial cells
-
Concentration:5 μM
-
Incubation Time:8 h
-
Result:Significantly blocked RV-induced phosphorylation (activation) of AKT.
Reversed RV-induced suppression of p53 protein expression in ARPE-19 cells.
-
Cell Line:ARPE-19 retinal pigment epithelial cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Completely abrogated RV-induced ARPE-19 cell proliferation that was 1.6 fold compared to control.
-
Cell Line:ARPE-19 retinal pigment epithelial cells
-
Concentration:2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited RV-induced ARPE-19 cell migration in a dose-dependent manner.
-
Cell Line:PANC-1 cells
-
Concentration:2.5 μM, 5 μM, 7.5 μM, 10 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Inhibited PANC-1 cells viability in a concentration- and time-dependent manner.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM
-
Incubation Time:48 h
-
Result:Dose-dependently elevated G0/G1 fraction while reducing S and G2/M populations, inducing G0/G1 arrest.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM
-
Incubation Time:48 h
-
Result:Persistently suppressed clonogenic capacity and long-term proliferation of pancreatic cancer cells.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM, 10 μM
-
Incubation Time:48 h
-
Result:Induced pancreatic cancer apoptosis in a dose-dependent manner.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM, 10 μM
-
Incubation Time:48 h
-
Result:Dose-dependently elevated LC3-II/LC3-I ratio; co-incubation with CQ further accumulated LC3B, confirming enhanced autophagic flux.
Downregulated phosphorylation of mTOR and its downstream p70S6K, S6 in both dose- and time-dependent manner, suppressing mTOR pathway activity.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM, 10 μM
-
Incubation Time:48 h
-
Result:Promoted formation of autophagic vacuoles in pancreatic cancer cells.
Accelerated autophagosome-lysosome fusion and intact autophagic degradation flux.
-
Cell Line:PANC-1 cells
-
Concentration:6 μM, 8 μM
-
Incubation Time:48 h
-
Result:Enhanced lysosomal acidification to facilitate autophagic substrate degradation.
In Vivo
Chalcomoracin (50 mg/kg; i.p.; once daily; 7 days) alone achieves 76.4% tumor growth inhibition, and (50 mg/kg; i.p.; once daily; 7 days + 10 Gy ionizing radiation; single dose) combined with ionizing radiation achieves 95.7% tumor growth inhibition in H460 xenograft nude mice via upregulation of endoplasmic reticulum stress markers and activation of p-Erk, without increasing apoptosis or causing obvious toxicity[2].
Chalcomoracin (30-55 mg/kg; i.p.; once daily; 21 days) inhibits MDA-MB-231 xenograft tumor growth in nude mice with 46% and 54% tumor growth inhibition at 30 mg/kg and 55 mg/kg, respectively, via inducing mitophagy and paraptosis without causing significant weight loss[3].
Chalcomoracin (20 mg/kg; p.o.; once daily; 21 days) inhibits pancreatic cancer xenograft growth with a 61.63% tumor inhibition rate via mTOR downregulation, autophagy induction and apoptosis promotion, but shows no efficacy (0% inhibition rate) in Atg7-knockdown xenografts, confirming its autophagy-dependent anti-tumor activity[5].
Chalcomoracin (20 mg/kg; i.p.; once daily; 27 days) inhibits pancreatic cancer xenograft growth with a 47.80% tumor inhibition rate via ROS-mediated mTOR pathway downregulation, autophagy induction, and apoptosis promotion, and this efficacy is abolished by NAC co-treatment[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 7 consecutive days
-
Result:Significantly reduced tumor volume compared to controls.
Significantly reduced average tumor weight compared to controls.
Showed little change in mouse body weight, while control group body weight decreased significantly.
Significantly reduced levels of phosphorylated ERK, phosphorylated P38, and phosphorylated JNK in tumor tissue compared to controls.
-
Animal Model:Nu/Nu nude mice (female, 5-7 weeks of age, subcutaneous inoculation of 5×106 H460 human large cell lung cancer cells)[2]
-
Dosage:50 mg/kg (monotherapy); 50 mg/kg + 10 Gy ionizing radiation (combination)
-
Administration:i.p.; once daily; 7 days (days 1-7); single dose ionizing radiation (day 1, combination only)
-
Result:Achieved 76.4% tumor growth inhibition (TGI).
Achieved 95.7% TGI when combined with ionizing radiation, which was significantly enhanced compared to monotherapy.
Upregulated endoplasmic reticulum stress markers Bip and Chop, and activated p-Erk in xenograft tumor tissues.
Reduced Ki67 staining in tumor tissues, with further enhancement observed in combined treatment.
Did not increase ionizing radiation-induced cleaved caspase 3 staining in tumor tissues.
Caused no obvious body weight changes in treated mice, indicating good tolerability.
-
Animal Model:Foxn1nu (female, 5-7 weeks of age, subcutaneous MDA-MB-231 xenograft)[3]
-
Dosage:30 mg/kg; 55 mg/kg
-
Administration:i.p.; once daily; 21 days
-
Result:Achieved 46% tumor growth inhibition at 30 mg/kg.
Achieved 54% tumor growth inhibition at 55 mg/kg.
Caused no significant weight loss in treated mice.
Upregulated PINK1, LC3-II, GRP78, and ubiquitinated proteins in tumor tissue.
Downregulated Alix in tumor tissue.
Activated ERK1/2 in tumor tissue.
Showed no changes in PARP or caspase-3 in tumor tissue.
Increased LC3-II-positive cells confirmed via immunohistochemistry.
Revealed cytoplasmic vacuolation in tumor tissues via H&E staining.
Induced dose-dependent increases in calpain 1 protein levels via immunofluorescence.
-
Animal Model:BALB/c nude (female, 5 weeks old, 18 g, subcutaneous xenograft model injected with PANC-1 sh-NC cells)[5]
-
Dosage:20 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Achieved a 46.09% T/C rate and 61.63% tumor inhibition rate.
Downregulated p-mTOR/mTOR and p-S6/S6 levels in tumor tissues.
Upregulated cleaved Caspase-3 expression in tumor tissues.
Increased the LC3-II/LC3-I ratio in tumor tissues.
Elevated LC3B and cleaved Caspase-3 levels in tumors as confirmed by immunohistochemistry and immunofluorescence.
Caused no significant change in mouse body weight, indicating no overt toxicity.
Achieved a 124.07% T/C rate and 0% tumor inhibition rate.
Failed to increase LC3-II and cleaved Caspase-3 levels in Atg7-knockdown tumors.
Showed no significant effect on p-mTOR/mTOR or p-S6/S6 levels relative to the vehicle group.
Caused no significant change in mouse body weight.
-
Animal Model:BALB/c nude (female, 5 weeks old, 18 g, subcutaneous xenograft model injected with PANC-1 cells)[5]
-
Dosage:20 mg/kg
-
Administration:i.p.; daily; 27 days
-
Result:Alone achieved a 52.50% T/C rate and 47.80% tumor inhibition rate.
Alone downregulated p-mTOR/mTOR and p-S6/S6 levels in tumor tissues.
Alone upregulated cleaved Caspase-3 expression in tumor tissues.
Alone increased the LC3-II/LC3-I ratio in tumor tissues.
Concurrent NAC treatment reversed these effects, resulting in a 172.11% T/C rate and 0% tumor inhibition rate, with no significant change in autophagy or apoptosis markers relative to the NAC-only group.
Caused no significant change in mouse body weight across groups.
Chemical Information
-
CAS. Nr. 76472-89-4
-
Molecular Weight 648.70
-
Formel C39H36O9
-
SMILES
O=C(C1=C(C(C/C=C(C)\C)=C(C=C1)O)O)[C@H]2[C@@H](C3=C(C=C(C4=CC5=CC=C(O)C=C5O4)C=C3O)O)C=C(C[C@@H]2C6=C(C=C(C=C6)O)O)C
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Mitophagy Solutions
Mitophagy is the selective autophagic degradation of mitochondria and functions as a mitochondrial quality-control pathway that removes damaged, depolarized, excess, or developmentally programmed mitochondria. The pathway links mitochondrial damage recognition, autophagosome recruitment, lysosomal delivery, and mitochondrial turnover to phenotypes such as mitochondrial homeostasis, oxidative-stress control, metabolic remodeling, differentiation, and neurodegeneration-related mitochondrial fidelity. The best-characterized damage-induced pathway is the PINK1-Parkin axis. Parkin is recruited selectively to impaired mitochondria and promotes their autophagic elimination, while mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, recruits Parkin, and activates Parkin-dependent mitophagy. PINK1 also phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity, and PINK1-driven ubiquitin phosphorylation creates a feed-forward signal for recruiting autophagy machi
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Reinheit & Dokumentation
Verweise
[1]. Cui Y, et al. Chalcomoracin promotes apoptosis and endoplasmic reticulum stress in hepatocellular carcinoma cells. The Journal of antibiotics. 2024 Jul;77(7):428-435. [Content Brief]
[2]. Zhang SR, et al. Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis. Acta pharmacologica Sinica. 2020 Jun;41(6):825-834. [Content Brief]
[3]. Han H, et al. Chalcomoracin is a potent anticancer agent acting through triggering Oxidative stress via a mitophagy- and paraptosis-dependent mechanism. Scientific reports. 2018 Jun 22;8(1):9566. [Content Brief]
[4]. Han H, et al. Chalcomoracin prevents vitreous-induced activation of AKT and migration of retinal pigment epithelial cells. Journal of cellular and molecular medicine. 2021 Oct;25(19):9102-9111. [Content Brief]
[6]. Liu Y, et al. Isolation of Chalcomoracin as a Potential α-Glycosidase Inhibitor from Mulberry Leaves and Its Binding Mechanism. Molecules (Basel, Switzerland). 2022 Sep 06;27(18):5742. [Content Brief]
[7]. Kim YJ, et al. Chalcomoracin and moracin C, new inhibitors of Staphylococcus aureus enoyl-acyl carrier protein reductase from Morus alba. Biological & pharmaceutical bulletin. 2012;35(5):791-5. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)